• +1-646-491-9876
    • +91-20-67278686

    Search

    Myasthenia Gravis - Pipeline Review, H1 2017

    Myasthenia Gravis - Pipeline Review, H1 2017

    • Report Code ID: RW0001689429
    • Category Healthcare
    • No. of Pages 110
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H1 2017, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

    Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

    Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
    - The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Myasthenia Gravis - Overview
    Myasthenia Gravis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Myasthenia Gravis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Myasthenia Gravis - Companies Involved in Therapeutics Development
    Achillion Pharmaceuticals Inc
    Alexion Pharmaceuticals Inc
    Alpha Cancer Technologies Inc
    Apellis Pharmaceuticals Inc
    arGEN-X BV
    BioMarin Pharmaceutical Inc
    CuraVac Inc
    GlaxoSmithKline Plc
    Grifols SA
    HanAll Biopharma Co Ltd
    Karus Therapeutics Ltd
    Millennium Pharmaceuticals Inc
    Neurotune AG
    Novartis AG
    Pfizer Inc
    Ra Pharmaceuticals Inc
    Regenesance BV
    Shire Plc
    Toleranzia AB
    UCB SA
    Myasthenia Gravis - Drug Profiles
    ACT-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amifampridine phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APL-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARGX-113 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    belimumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bortezomib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CFZ-533 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CVMG-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eculizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GL-2045 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HL-161 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KA-1463 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    methotrexate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit C1q for Myasthenia Gravis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NT-1654 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RA-101495 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Myasthenia Gravis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Regenemab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rozanolixizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SM-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TK-21 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Myasthenia Gravis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Myasthenia Gravis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Myasthenia Gravis - Dormant Projects
    Myasthenia Gravis - Discontinued Products
    Myasthenia Gravis - Product Development Milestones
    Featured News & Press Releases
    Jan 09, 2017: Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG)
    Jan 06, 2017: argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis
    Jan 04, 2017: Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016
    Dec 01, 2016: argenx to provide update on ARGX-113 during American Society of Hematology Annual Meeting
    Sep 30, 2016: Toleranzia completes Eurostars project according to plan and postpones start of clinical study
    Sep 22, 2016: argenx provides update on lead program ARGX-113 at R&D day in New York
    Sep 02, 2016: Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for the Treatment of Myasthenia Gravis
    Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress
    Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
    Feb 08, 2016: Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia Gravis
    Jan 26, 2016: Toleranzia takes an important step towards patent granting in Europe
    May 29, 2015: Double recognition of Toleranzia
    Feb 26, 2015: Toleranzias Receives Orphan Drug Designation For Myasthenia Gravis
    Feb 25, 2015: HanAll BioPharma Receives a Grant for HL161 Auto-Immune Project from Korean Drug Development Fund
    Dec 10, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Myasthenia Gravis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Myasthenia Gravis - Pipeline by Achillion Pharmaceuticals Inc, H1 2017
    Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H1 2017
    Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H1 2017
    Myasthenia Gravis - Pipeline by Apellis Pharmaceuticals Inc, H1 2017
    Myasthenia Gravis - Pipeline by arGEN-X BV, H1 2017
    Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H1 2017
    Myasthenia Gravis - Pipeline by CuraVac Inc, H1 2017
    Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H1 2017
    Myasthenia Gravis - Pipeline by Grifols SA, H1 2017
    Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H1 2017
    Myasthenia Gravis - Pipeline by Karus Therapeutics Ltd, H1 2017
    Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Myasthenia Gravis - Pipeline by Neurotune AG, H1 2017
    Myasthenia Gravis - Pipeline by Novartis AG, H1 2017
    Myasthenia Gravis - Pipeline by Pfizer Inc, H1 2017
    Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H1 2017
    Myasthenia Gravis - Pipeline by Regenesance BV, H1 2017
    Myasthenia Gravis - Pipeline by Shire Plc, H1 2017
    Myasthenia Gravis - Pipeline by Toleranzia AB, H1 2017
    Myasthenia Gravis - Pipeline by UCB SA, H1 2017
    Myasthenia Gravis - Dormant Projects, H1 2017
    Myasthenia Gravis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Myasthenia Gravis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Achillion Pharmaceuticals Inc
    Alexion Pharmaceuticals Inc
    Alpha Cancer Technologies Inc
    Apellis Pharmaceuticals Inc
    arGEN-X BV
    BioMarin Pharmaceutical Inc
    CuraVac Inc
    GlaxoSmithKline Plc
    Grifols SA
    HanAll Biopharma Co Ltd
    Karus Therapeutics Ltd
    Millennium Pharmaceuticals Inc
    Neurotune AG
    Novartis AG
    Pfizer Inc
    Ra Pharmaceuticals Inc
    Regenesance BV
    Shire Plc
    Toleranzia AB
    UCB SA

    Request for Sample

    Report Url http://www.reportsweb.com//myasthenia-gravis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//myasthenia-gravis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//myasthenia-gravis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments